Early data from Regeneron Pharmaceuticals, Inc.’s REGN-COV2 shows the antibody cocktail has promise in treating non-hospitalized COVID-19 patients, with the most significant results in individuals who have not mounted an antibody response against the infection.
The first data from a descriptive analysis of the first 275 patients treated in a seamless Phase I/II/III trial showed...






